FOCP's ‘Pink October' encourages corporates and institutions to participate in Breast Cancer Awareness month
Pink October focuses on early breast cancer detection and awareness.
It offers free mammogram screenings and clinical breast examinations through mobile clinics.
The initiative provides educational sessions and workshops on breast self-examination for both women and men.
Corporate participation is encouraged through tailored packages, including mobile clinic bookings and Corporate Wellness Days.
The campaign aims to empower communities, reduce breast cancer rates, and promote proactive health checks.
Sharjah: The Friends of Cancer Patients (FOCP) has launched its Pink October campaign to promote early breast cancer detection through community education and accessible screening programs. The campaign, delivered through FOCP's Pink Caravan initiative, aims to raise awareness and ensure individuals have the knowledge and resources necessary to prioritise their breast health
To provide tailored support and awareness to the UAE workforce, FOCP encourages companies and institutions across the nation to play a crucial role in the ongoing fight against breast cancer by partnering with the Pink Caravan and making its vital services accessible to their employees.
Social responsibility and awareness
Corporate participation is essential in amplifying the reach and impact of breast cancer awareness efforts. By partnering with the Pink Caravan initiative, companies can demonstrate their commitment to social responsibility and actively contribute to enhancing the health and well-being of women and men in the workplace.
'Early detection saves lives and it's a responsibility we all share,' said Aisha Al Mulla, Director of FOCP. 'In the UAE, companies and corporations are pillars of our community, so their platforms, networks, and influence can play a transformative role in promoting awareness, encouraging screenings, and supporting a culture of proactive health. Through our Pink October campaign, we urge business leaders and industry decision-makers to step up, speak out, and join us in championing the importance of early detection. Together, we can build a healthier, stronger, and more resilient society.'
Tailored options for corporate and institutional entities
This year's Pink October campaign offers a range of tailored solutions to encourage corporate involvement, designed to make participation impactful and effective. Companies can book Pink October's mobile clinic to visit their premises, providing expert-led mammogram screenings for female employees aged 40 and above, as well as clinical breast examinations for women and men aged 20 and above. These services are delivered with the utmost professionalism and privacy, ensuring a comfortable and supportive experience for all participants.
For organisations seeking a comprehensive approach to employee health, the Pink October Corporate Wellness Day is ideal, combining clinical breast examination, mammogram vouchers, and engaging awareness lectures that empower staff with life-saving knowledge.
In addition to these core offerings, companies can also benefit from Mini Mobile Clinics, which provide screening services at the workplace. They can also book awareness seminars and workshops, available both onsite and online. These educational sessions are designed for both women and men, covering the essentials of breast self-examination and the importance of early detection. They are complemented by informative brochures distributed to all attendees.
The impact of Pink Caravan and their Pink October campaign is clear, and year after year, thousands of women and men across the UAE gain access to screenings and educational resources, thanks to the support of forward-thinking corporate partners.
Corporate bookings for the Pink October campaign are now open, and to reserve your Mobile Clinic, Corporate Wellness Day, or Awareness Seminar, simply email the Pink October team at info@pinkcaravan.ae.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
2 hours ago
- Zawya
DHA grants initial approval to Yas Healthcare to set up UAE's first proton therapy centre in Dubai
The Dubai Health Authority (DHA) has accorded initial approval to Yas Healthcare, a subsidiary of Das Holding, to establish the UAE's first proton therapy centre in Dubai, marking a historic milestone in the advancement of cancer care in the region. The state-of-the-art facility is expected to be completed by late 2028, with construction slated to start in early 2026. It will be the first dedicated centre in the UAE to offer proton therapy, a highly advanced and precise form of radiation therapy that targets tumours with exceptional accuracy while sparing healthy tissue. The treatment is especially effective for paediatric cancers and tumours located near sensitive organs. Dr. Alawi Alsheikh-Ali, Director-General, Dubai Health Authority, stated, 'Under the visionary leadership of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister, and Ruler of Dubai, and H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of The Executive Council of Dubai, we are committed to positioning Dubai as a global leader in healthcare. This proton therapy centre will enhance patient care, offering world-class, patient-centred treatment and improving access to specialised care that ensures better outcomes. 'This groundbreaking technology will advance cancer treatment options for our community and reinforce Dubai's goal of ranking among the top 10 cities globally for healthy life expectancy. It also strengthens Dubai's position as a key destination for advanced medical care and innovation, in line with the National Strategy for Wellbeing 2031, Dubai Social Agenda 33, and the Dubai Economic Agenda D33.' Proton therapy is a highly precise and advanced radiation treatment that delivers targeted doses to cancerous tumours while sparing surrounding healthy tissue. This minimises side effects and is particularly effective for treating paediatric cancers and complex or sensitive tumour sites. The Yas Proton Therapy Centre will provide patients across the region with access to this specialised treatment for the first time, eliminating the need to travel abroad for care. The project will be developed in strategic collaboration with the National Cancer Centre Singapore (NCCS), one of Asia's leading authorities in oncology. NCCS will serve as the project consultant, bringing global clinical and technical expertise to the design and implementation of the facility. Dr. Mohamad Zaki, Medical Director and General Manager of Yas Healthcare, said, 'Global data indicates a rising number of cancer diagnoses, particularly among younger patients. Proton therapy provides a treatment option with fewer side effects and lower toxicity for certain cancer types. The Yas Proton Therapy Centre aims to improve accessibility and reduce costs by offering this treatment closer to home.' Dr. Michael Wang, Chair of the Division of Radiation Oncology at the National Cancer Centre Singapore, added, 'This milestone collaboration with Yas Healthcare reflects the National Cancer Centre Singapore's leadership in radiation oncology, operating one of the largest proton beam facilities in Southeast Asia. We are excited to contribute our expertise as Yas Healthcare introduces this advanced technology to redefine cancer treatment in the GCC.' The move to develop the new facility directly aligns with the National Strategy for Wellbeing 2031, the Dubai Social Agenda 33, and the Dubai Economic Agenda D33 — key initiatives to enhance quality of life, improve health outcomes, and position Dubai as a premier destination for medical innovation and tourism. Dubai's Medical Tourism Vision also aims to attract more than 500,000 international patients annually by 2025. Construction work related to the project is scheduled to begin in early 2026 and the facility is expected to be operational by the end of 2028. Yas Healthcare's official platforms will provide updates on the progress of the project and patient enrolment programmes.
Zawya
2 hours ago
- Zawya
Aster Volunteers UAE recycles 750 kgs of e-waste in 4th collection drive
To date, the initiative has cumulatively recycled 1,998 kgs of e-waste over the four editions. Partnered with E-Scrappy and engaged Asterians in collecting e-waste from nearby shops and homes, demonstrating community involvement and support. A similar activity has been initiated across Qatar, Oman, KSA and India. UAE: Aster Volunteers UAE, the global CSR arm of Aster DM Healthcare, recently organized an impactful 4th E-Waste Collection Drive as part of the 'Aster Green Choices initiative', reinforcing Aster DM Healthcare's unwavering commitment to environmental sustainability. Collection boxes were strategically placed in nine Aster units across the UAE, including Aster Jubilee Medical Centre Bur Dubai, Aster Hospital Mankhool, Aster Hospital Qusais, Aster Hospital Sharjah, Medcare Orthopedics and Spine Hospital, Medcare Al Safa, Aster Clinic Al Warqa, Aster Corporate Office Al Diyafah, Aster Retail Warehouse – Dubai Investment Park, and Aster Cedars Hospital & Clinic, Jebel Ali. Additionally, Medcare Royal Specialty Hospital Qusais and Medcare Hospital Sharjah supported the initiative by contributing some e-waste. The drive resulted in the recycling of 750 kgs of e-waste in collaboration with E-Scrappy. To date, the initiative has cumulatively recycled 1,998 kgs of e-waste over the four editions. The drive not only highlighted the importance of proper e-waste disposal but also educated the public on the environmental impact of electronic waste, encouraging more sustainable practices across the UAE. Over the years, the initiative has successfully recycled 496 kgs of e-waste in 2020, 318 kgs in 2023, 434 kgs in 2024 and now 750 kgs in 2025. Asterians from various units played a crucial role by collecting e-waste from nearby shops and bringing electronic waste from their homes to designated collection boxes. The collected e-waste was responsibly recycled by E-scrappy, who issued a Green Certificate to Aster Volunteers UAE, underscoring their commitment to environmental management. Dr. Azad Moopen, Founder Chairman, Aster DM Healthcare, commented on the initiative, stating, 'Our commitment to environmental sustainability continues to be a core pillar of Aster's mission, guided by our ESG framework and alignment with 10 of the 17 UN Sustainable Development Goals. Aligned with the spirit of World Environment Day, with each edition of the E-Waste Collection Drive, we build greater awareness about the importance of responsible e-waste disposal and foster a culture of recycling within our communities. The success and continued growth of this initiative reaffirm our belief that collective action can drive meaningful environmental impact. Alongside efforts like tree plantations, indoor and seed plant distributions, and clean-up drives, the E-Waste Collection Drive reflects our enduring dedication to a greener, more sustainable future.' The E-Waste Collection Drive is part of Aster DM Healthcare's broader environmental sustainability strategy, which includes other countries like Qatar, KSA, Oman, and India. The company's long-term goals focus on mitigating the environmental impact of toxins leached from buried metals, ensuring the proper disposal and recycling of e-waste. Over the last few years, Aster Volunteers has emerged into a global movement driven by over 85,000 volunteers who have impacted over 6.5 million lives. Aster DM Healthcare GCC achieved a significant reduction of 541 tCO2e in net greenhouse gas emissions through the integration of solar energy sources, including 1,340,000 KWh of solar energy as on 31st March 2024. The company also excelled in waste management, recycling 64,871 kilograms of waste, including 3,992 kilograms of plastic waste, 2,835 kilograms of paper waste, and 434 kilograms of e-waste. The organization prioritizes waste segregation at the source, enabling efficient recycling of biomedical, plastic, food, metals, paper, and cardboard waste. Aster's Annual ESG Report for FY 23-24 highlighted a reduction of 1,769 KL in water consumption across nine hospitals. Social initiatives under Aster Volunteers have significantly contributed to community health, disaster aid, and social empowerment programs. Aster DM Healthcare, one of the largest integrated healthcare providers in the GCC, has received three prestigious awards from the Dubai Chamber of Commerce and Arabia CSR Awards for its sustainability, corporate social responsibility (CSR), and community initiatives. Recognized with the 'Advanced CSR Label for 2022' by the Dubai Chamber, Aster has excelled in Workplace, Marketplace, Community, and Environment impact areas for four consecutive years. The company integrates 10 UN Sustainable Development Goals (UN SDGs) into its ESG policies through initiatives like Aster Volunteers, impacting communities globally. Aster also signed the Action Declaration on Climate Policy Engagement at COP27 and was the only Middle Eastern and Indian company listed among Corporate Knights' Global 100 sustainable companies for 2022, showcasing its commitment to building sustainable organizations. Looking ahead, Aster DM Healthcare aims to continue its commitment to environmental sustainability by organizing more e-waste collection drives and other green initiatives. The organization's long-term goals include reducing carbon emissions, increasing the use of renewable energy, and promoting sustainable practices across all its operations. About Aster Volunteers, the global CSR programme of Aster DM Healthcare Launched in 2017, Aster Volunteers serves as the global CSR arm of Aster DM Healthcare. This initiative embodies the spirit of giving back to society and has touched the lives of over 6.5 million people through various programs with more than 85,000 registered volunteers. Key activities include disaster relief efforts, mobile medical services, free or subsidized surgeries for the needy, medical camps, blood donation drives, and health awareness campaigns. Aster Volunteers focuses on sustainable and impactful solutions, particularly in women's empowerment, education, and social upliftment. For more information about us, please contact:
The National
6 hours ago
- The National
Emirati man with rare blood disorder benefits from new $2 million gene therapy in the US
An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 million gene therapy that eliminates the need for regular blood transfusions. Khalifa Dawood, 22, from Abu Dhabi said he has been given a 'new lease on life' as he recovers from the novel gene treatment he received at Cleveland Clinic Children's hospital in Ohio, which recently won medical approval for the therapy. The UAE has some of the regions highest rates of thalassaemia, also known as sickle cell disease, a condition that limits the body's ability to produce healthy red blood cells. While some carriers show very limited symptoms, others experience bone deformities, shortness of breath, dizziness, organ damage and heart palpitations. The condition can require regular blood transfusions, with research suggesting thalassaemia affects as many as 16.5 per cent of the population. A new treatment used for the first time by the Cleveland Clinic Children's hospital has proven to modify a patient's blood forming cells, and can be delivered as a one-time treatment called Casgevy. Mr Dawood said that he hoped the treatment would allow him to lead a normal life, without the need for regular hospital stays. 'I am hoping this gives me a new lease on life where I am energised to enjoy it,' he said. Life-changing treatment Since its approval by the US Food and Drug Administration in January, the therapy has been delivered to an American woman from Ohio and Mr Dawood. I am hoping this gives me a new lease on life where I am energised to enjoy it Khalifa Dawood Although the treatment is expensive, it is life changing for those who receive it, according to Dr Rabi Hanna, chairman of the paediatric haematology-oncology department at Cleveland Clinic Children's hospital. It is not uncommon for adults to receive specialist care at a children's centre, particularly for conditions they have had since birth, as is the case with Mr Dawood. 'Unlike regular medicines that people take for years, Casgevy is meant to be a one-time treatment that could last a lifetime,' he said. 'It uses CRISPR gene editing, which is a very advanced science. Editing cells safely and precisely takes a lot of time, technology, and testing. 'It is also custom-made, as Casgevy is made from a person's own cells, which are collected, sent to a lab, edited and then returned. That process is complex and individualised.' The innovative treatment uses a gene editing technology called CRISPR/Cas9 to modify a patient's stem cells. The edited cells are then transplanted back into the patient, where they produce more haemoglobin in new healthy red blood cells. The FDA's approval was based on results from a single arm which showed 91 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment. Costly medical care Despite the therapy's success, it is likely to remain out of reach for the majority with costs of about $2.2 million. Gene therapies are typically the most expensive medical treatments. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of haemophilia B, a potentially life threatening disorder that prevents blood from clotting. Priced at about $3.5 million, it was the world's most expensive drug until the arrival of Lenmeldy in March last year. The gene treatment developed by Orchard Therapeutics costs about $4.2 million and is used to treat life threatening nerve disorders in young children. High costs of certain drugs can be covered by insurers, government health systems or charitable foundations when there are no other treatment options. Drug companies also occasionally offer financial support programmes for families in need. The process of administering Casgevy begins by collecting stem cells from the patient's blood that are then sent to the lab to be edited using tiny, precise scissors. By clipping off the DNA responsible for preventing the body making healthy haemoglobin, the repaired cells can then be returned to the body. A course of chemotherapy is then required to clear out the old, sick marrow cells, allowing new healthy ones to grow in their place. Recovery time in the hospital is about four weeks. As the science behind gene editing improves, it should become faster, easier and cheaper to edit cells with higher accuracy, and fewer side effects. 'It is my hope and prediction that price will come down, but I am not sure how quickly,' said Dr Hanna. 'As the science of gene editing improves, it may become faster, easier, and cheaper to edit cells with higher accuracy and fewer side effects. 'Right now, Casgevy is the first gene editing therapy approved for sickle cell and thalassaemia. 'But more companies are developing similar treatments. When that happens, competition can help drive prices down. 'Also as companies learn how to make these therapies at scale, they may reduce production and delivery costs. 'Think of it like early computers or smartphones – they were expensive at first, but prices dropped as technology improved.' Global health drive Although patients like Mr Dawood must travel overseas for expensive gene therapy, the Gulf is also emerging as a go-to destination for emerging treatments. The King Faisal Specialist Hospital & Research Centre in Saudi Arabia is emerging as a leader of regional clinical trials and delivered a breakthrough in haemophilia care, using one-time gene therapy to restore clotting function in eight patients. In the UAE, at Medcare Royal Speciality Hospital Al Qusais, patients are receiving the latest care for rare genetic disorders like spinal muscular atrophy and Duchenne muscular dystrophy, two life-limiting growth conditions. Doctors there said patients were travelling into Dubai from Turkey and elsewhere in the region. Medcare Women and Children Hospital was one of the first private clinics outside the US to administer gene therapy for spinal muscular atrophy, and has since delivered 100 infusions. American Hospital, Al Jalila Children's Hospital and Fakeeh University Hospital also offer gene therapy Zolgensma, which can cost about $2 million per dose. Dr Vivek Mundada, a consultant paediatric neurologist at Medcare Royal Speciality Hospital, said the drug had delivered remarkable outcomes in managing complex genetic conditions. 'Dubai is becoming a centre of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' he said. 'Through our comprehensive, patient-centred care model, we are transforming outcomes for children who previously had limited treatment options.'
